On November 5, GlaxoSmithKline PLC rose 4.3% in Regular Trading, trading at $50.81 per share, with turnover of $128 million.
The latest catalyst in publicly available reports was a new research collaboration with Alamar Biosciences, which said it will use its Nulisa platform with GlaxoSmithKline PLC to study circulating protein signatures and disease progression, highlighting continued investment in early research tools.
The move also comes shortly after third-quarter results that beat revenue and adjusted EPS expectations while full-year guidance was reaffirmed. GlaxoSmithKline PLC reported revenue of 8.89 billion pounds, up 4% year over year, and adjusted EPS of $1.47, above the $1.40 consensus. Growth in oncology, respiratory and immunology, and HIV helped offset pressure in vaccines. Although Jefferies downgraded the stock to Hold with a $55.90 target and RBC trimmed its London target to 19.25 pounds while keeping Sector Perform, reported targets remained above the current share price, leaving valuation and growth expectations under active debate.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments